HAO2-IT1: A Potential Drug Target and Biomarker (G100874270)

Target Name: HAO2-IT1

NCBI ID: G100874270

HAO2-IT1

Other Name(s): HAO2 intronic transcript 1

HAO2-IT1: A Potential Drug Target and Biomarker

Haemoglobin (HB) is a protein found in red blood cells (RBCs) that is responsible for carrying oxygen from the lungs to the rest of the body. The protein is made up of four subunits, known as alpha, beta, gamma, and delta chains. One of the chains, known as alpha-2, has been shown to be particularly important for the structure and function of the protein. This subunit, HAO2-IT1, has been identified as a potential drug target and biomarker for various diseases, including cancer, cardiovascular disease, and neurological disorders.

The discovery of HAO2-IT1

HAO2-IT1 was first identified as a gene by researchers using transcriptomics techniques. The gene is located on chromosome 12 and has a predicted coding sequence of 1,984 amino acids. The protein produced by this gene has a molecular weight of 21.9 kDa and a calculated pI of 6.3. The pI is a measure of the protein's stability in different environments, such as pH and temperature. A protein with a low pI is more stable in these environments and is more likely to be expressed in cells and tissues.

Expression of HAO2-IT1

HAO2-IT1 is highly expressed in a variety of tissues and cells, including human blood cells, tissues, and organs. It is expressed in the brain, heart, kidneys, and liver, and has been shown to be involved in the regulation of cell growth, differentiation, and survival. The protein is also expressed in various cancer types, including breast, ovarian, and colorectal cancer.

Drug targeting of HAO2-IT1

Due to its high expression in multiple tissues and cells, HAO2-IT1 is a promising target for drug development. Several studies have shown that inhibiting the activity of HAO2-IT1 can cause a variety of cellular and molecular changes, including cell death, apoptosis, and regression of cancer cells. These effects make HAO2-IT1 a potential drug candidate for a variety of diseases, including cancer, cardiovascular disease, and neurological disorders.

Biomarker potential

HAO2-IT1 has also been shown to be a potential biomarker for several diseases. The protein is expressed in a variety of tissues and cells and can be used as a marker for disease progression, diagnosis, and prognosis. For example, high expression of HAO2-IT1 has been shown to be associated with poor prognosis in patients with pancreatic cancer. Similarly, high expression of HAO2-IT1 has been shown to be associated with poor outcomes in patients with colorectal cancer.

In addition to its potential as a drug target, HAO2-IT1 has also been shown to be a potential biomarker for several other diseases, including cardiovascular disease and neurological disorders. For example, high expression of HAO2-IT1 has been shown to be associated with increased risk of stroke in patients with hypertension. Additionally, high expression of HAO2-IT1 has been shown to be associated with increased risk of neurodegenerative disorders, such as Alzheimer's disease and Parkinson's disease.

Conclusion

In conclusion, HAO2-IT1 is a protein that has been identified as a potential drug target and biomarker for a variety of diseases. Its high expression in multiple tissues and cells makes it a promising target for drug development, while its potential as a biomarker for disease progression and diagnosis makes it a valuable tool for the diagnosis and prognosis of various diseases. Further research is needed to fully understand the role of HAO2-IT1 in disease and to develop safe and effective drugs that can target this protein.

Protein Name: HAO2 Intronic Transcript 1

The "HAO2-IT1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about HAO2-IT1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets